The breast cancer patients saw a decrease in the average VEGF-A plasma concentration from 52.9 μg/mL to 43.8 μg/mL and their MMP-9 levels dropped from an average of 237.8 ng/mL to 109.6 ng/mL. Here, MMP9 is linked to breast carcinoma.